Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical stage, biopharmaceutical company dedicated to discovery, development, and commercialization of next-generation multi-functional biotherapeutics, initially focused on the treatment of cancer. In 2018 Flinn Ferguson Cresa was engaged by Zymeworks to search for their US based headquarters. Flinn Ferguson assembled an all star team of workplace/architects and construction & project managers to support Zymeworks, and the process resulted in the lease of 42,286 square feet at 1215 4th Avenue, a building on the Metropolitan Tract which is owned by the University of Washington and managed by Unico. Following initial occupancy in early 2020, Zymeworks expanded to take another 14,967 sf in April of 2021.
In mid-2022, leadership changes at the company emphasized a reduction in operating costs. In September of 2022 Flinn Ferguson successfully negotiated a termination of one of Zymeworks floors and is currently marketing another two floors for sublease with one of the floors pending a sublease.